ORGO - Organogenesis Holdings Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ORGO

ORGANOGENESIS HOLDINGS INC.

NASDAQ

$1.29

▲ UP 1.16% (0.01)

KEY STATISTICS

Market Cap$163.42 M

52w High$7.08

52w Low$1.25

Dividend Yield—

Frequency—

P/E43.16

Volume149.76K

Shares Out.128.67M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Gary S. Gillheeney

COMPENSATION 2026

Salary$979,105

Stock Awards$2,833,330

Incentive Plan Pay$1,536,575

All Other Comp.$82,727

Total$6,811,754

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 5, 2017

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

854

PRICE TARGET

Target High$3.00

Target Low$2.00

Target Median$2.50

Target Consensus$2.50

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$52.09M

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

42.43%

HOLDERS

182

TOP 8 OF 182 · RANKED BY POSITION SIZE

Soleus Capital Management, L.P.

First Light Asset Management, LLC

Assenagon Asset Management S.A.

PRICE

$1.29 ▲ UP 1.16% (+$0.01)

About Organogenesis Holdings Inc.

https://organogenesis.com ↗

Organogenesis Holdings Inc. develops and commercializes regenerative medicine solutions for wound care, surgical, and sports medicine markets in the U.S., including bioengineered tissues, membranes, and advanced healing products.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT ORGANOGENESIS HOLDINGS INC. IS KNOWN FOR

ReNu

ReNu is a cryopreserved amniotic allograft for knee osteoarthritis, FDA BLA pending, with positive phase 3 results, representing Organogenesis's key product and growth focus in surgical and sports medicine.

COMPETITORS

COMPETITOR

Organogenesis Holdings in 2025

SENTIMENT: + POSITIVE

EARNINGS · NOVEMBER 6, 2025

Organogenesis Holdings Reports Record Q3 Revenue and Raises 2025 Guidance, Sparking Significant Stock Rally

Organogenesis Holdings announced record financial results for the third quarter of 2025, reporting net product revenue of $150.5 million, a 31% increase year-over-year. This strong performance, driven by its Advanced Wound Care products, led the company to raise its full-year revenue and profitability guidance, signaling a significant positive turnaround from the financial losses reported in the first half of the year.

OPERATIONAL · MAY 2025 · IN PROGRESS

Organogenesis Announces Plans for New $100 Million Biomanufacturing Facility in Rhode Island to Expand Production and R&D Capabilities

Organogenesis unveiled plans for a new 122,000-square-foot biomanufacturing facility in Smithfield, Rhode Island. This significant investment is intended to expand manufacturing, laboratory, warehousing, and distribution capabilities to support the company's current product portfolio and future growth initiatives, including the planned resumption of commercial production for Dermagraft®.